News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Zeltia Group’s Yondelis to be Sold in Switzerland
February 6, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Feb 6 (Reuters) - Spanish biotechnology company Zeltia's (ZEL.MC) Yondelis drug has received approval to be sold in Switzerland to treat soft tissue sarcoma (STS), the company said in a statement on Friday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Approvals
Vanda Rebounds From Jet Lag Rejection With FDA Nod for Bipolar, Schizophrenia Drug
February 23, 2026
·
2 min read
·
Tristan Manalac
Insights
Historic ALS Investment Signals New Treatment Momentum
February 23, 2026
·
3 min read
·
Jennifer Smith-Parker
FDA
Makary, Prasad Under Fire as FDA Turmoil Reaches President Trump
February 20, 2026
·
6 min read
·
Heather McKenzie
